A. An OS benefit was observed in the pembrolizumab/platinum/5-FU arm. B. No OS benefit was observed in either treatment arms. C. A PFS benefit was observed in the pembrolizumab/platinum/5-FU arm. D. No PFS benefit was observed in either treatment arms. E. Unsure

A. 55% B. 85% C. 95% D. 99% E. Unsure

A. Preferred, Category 1 B. Preferred, Category 2A C. Appropriate in select circumstances, Category 2A D. Category 3 E. Unsure

A. OS and PFS were inferior to standard of care. B. PFS was observed with nivolumab. C. OS was observed with chemotherapy. D. OS was improved with nivolumab but no difference in PFS was observed. E. Unsure

A. Higher grade 3 or 4 events were observed with nivolumab vs standard of care. B. Higher grade 3 or 4 events were observed with standard of care vs nivolumab. C. Higher adverse events were observed with nivolumab 480 mg vs 240 mg doses. D. No difference in adverse events was observed. E. Unsure

A. Median OS was greater for the pembrolizumab arm only in PD-L1 positive patients compared to the standard-of-care arm. B. Median OS was greater for the pembrolizumab arm compared to the standard of care. C. Median OS was greater for the standard-of-care arm compared to the pembrolizumab arm. D. No difference in OS was observed. E. Unsure

A. Preferred, Category 1 B. Preferred, Category 2A C. Appropriate in select circumstances, Category 2A D. Category 3 E. Unsure

A. Discontinue pembrolizumab and initiate prednisone 1-2 mg/kg/d. B. Continue pembrolizumab and initiate topical triamcinolone cream BID-TID. C. Continue pembrolizumab and initiate infliximab 5 mg/kg once every 2 weeks. D. Switch from pembrolizumab to 5-FU chemotherapy. E. Unsure

A. Hold nivolumab and initiate loperamide 4 mg after the first loose stool followed by 2 mg with subsequent episodes. B. Hold nivolumab and initiate prednisone 1-2 mg/kg/d followed by a long taper upon resolution of diarrhea. C. Continue nivolumab and initiate loperamide 4 mg after the first loose stool followed by 2 mg with subsequent episodes. D. Hold nivolumab and initiate prednisone 1-2 mg/kg/d and loperamide 4 mg after the first loose stool followed by 2 mg with subsequent episodes. E. Unsure

A. Hold therapy and initiate prednisone 0.5-1 mg/kg/d. B. Evaluate thyroid function and initiate levothyroxine as appropriate. C. Continue therapy and initiate topical corticosteroids. D. Hold therapy and initiate infliximab 5 mg/kg once E. Unsure